Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MYELOMATCH Clinical Trials
Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided Therapies (LUMOS2)
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
NEoadjuvant chemoradiotherapy for Esophageal scc vs Definitive chemoradiotherapy with salvage Surgery as needed (NEEDS Trial)
The Canadian Cancer Trials Group (CCTG) Operations and Statistical Centre (OSC), based at the Queen’s University Cancer Research Institute in Kingston, Ontario is seeking a physician with hematology or oncology training with demonstrated interest and experience with developing and cancer therapy trials.
Senior investigators work at the OSC with members of the investigational new drug and disease-specific and trial endpoint committees, which have national investigator leadership and membership, to develop and implement the CCTG clinical trials research agenda.
The results of the Canadian Cancer Trials Group (CCTG) BL.12 phase II randomized trial were presented at ASCO 2018 by Dr. Srikala Sridhar, the BL.12 Study Chair. In this interview Dr. Sridhar discusses the BL.12 study and what is next for bladder cancer clinical trial research.
The Canadian Cancer Trials Group is currently seeking additional members for our Clinical Research Associates Executive Committee (CRAEC). Please feel free to distribute this call for volunteers within your clinical trials department, and encourage applications from interested and qualified individuals.
The Delegation of Tasks Log (DTL) has now been implemented by the Clinical Trials Evaluation Program (CTEP) for selected trials. The first National Clinical Trials Network (NCTN) trial where CCTG will be using the DTL is the BLC.4 trial. An active DTL has been added as a requirement for CCTG sites following approval of the BLC.4 Revision #3. Other studies that will be using the DTL initially include MAC.24 and REC.4.
The abstract for the RELEVANCE/LY.16 study was presented at ASCO on June 3rd, 2018. This study compared the effects of lenalidomide plus rituximab (R2) to chemotherapy plus rituximab (R-chemo) followed by rituximab maintenance in patients with previously untreated follicular lymphoma.
The CCTG TRIALBLAZERS have been training hard for this year’s Kingston Relay for Life, June 22, 2018 - 6:00 pm - 12:00 am.
The PRODIGE 24/CCTG PA.6 trial results suggest that this pancreatic cancer treatment regimen should become standard practice world-wide. Patients who receive this treatment after surgery are almost twice as likely to survive.
